Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis To Ship 55.4 Mil. Fluzone Doses For 2004-05 Flu Season

This article was originally published in The Pink Sheet Daily

Executive Summary

The Centers for Disease Control & Prevention is requesting that the influenza vaccine go to "high-risk" individuals. FDA scientists will tour Chiron's Liverpool manufacturing facility Oct. 9-10 following the U.K.'s decision to suspend the release of Fluvirin for three months.

You may also be interested in...



Flu Vaccine Allotment Plan Prioritizes States With Chiron Contracts

All states should receive at least half of their contracted influenza vaccine supply in the first phase of Sanofi-Aventis’ Fluzone dose distribution in cooperation with the CDC. Other “first phase” recipients will include the Vaccines for Children program, pediatricians with Aventis contracts.

Flu Vaccine Allotment Plan Prioritizes States With Chiron Contracts

All states should receive at least half of their contracted influenza vaccine supply in the first phase of Sanofi-Aventis’ Fluzone dose distribution in cooperation with the CDC. Other “first phase” recipients will include the Vaccines for Children program, pediatricians with Aventis contracts.

Flu Vaccine Manufacturers Look To Government To Increase Demand

Aventis, MedImmune believe that expanding the recommended population for influenza vaccine will drive demand and spur additional manufacturers to enter the market, companies tell Government Reform Committee hearing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel